Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

A 7-year-old girl with cystic fibrosis recently became a symbol of Libya's healthcare crisis. Her family undertook an illicit ...

ECMO use in cystic fibrosis with severe respiratory failure showed limited survival, highlighting the need for cautious ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

A 7-year-old girl with cystic fibrosis recently became a symbol of Libya's healthcare crisis. Her family undertook an illicit journey to Italy to get her the care their own country didn't provide.

Passage of the bill — which cuts critical health coverage for people with cystic fibrosis and their families — shows the ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

The small molecule CFTR modulators market targets cystic fibrosis treatment, driven by innovative therapies, rising prevalence ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Most children with CF treated at a San Francisco CF clinic did not receive CF liver disease screening in accordance with current guidelines.

Two brothers and two friends take on and wi, an 80-mile Atlantic paddleboard challenge in an effort to provide support for ...

This shift follows the announcement of initial positive data from the Phase 1/2 clinical trial of PM359 in Chronic ...